Skip to main content
Top
Published in: Journal of Gastroenterology 4/2019

Open Access 01-04-2019 | Original Article—Liver, Pancreas, and Biliary Tract

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update

Authors: Ryosuke Tateishi, Koji Uchino, Naoto Fujiwara, Tetsuo Takehara, Takeshi Okanoue, Masataka Seike, Hitoshi Yoshiji, Hiroshi Yatsuhashi, Masahito Shimizu, Takuji Torimura, Mitsuhiko Moriyama, Isao Sakaida, Hiroyuki Okada, Tetsuhiro Chiba, Makoto Chuma, Kazuhiko Nakao, Hajime Isomoto, Yutaka Sasaki, Shuichi Kaneko, Tsutomu Masaki, Kazuaki Chayama, Kazuhiko Koike

Published in: Journal of Gastroenterology | Issue 4/2019

Login to get access

Abstract

Background

We previously reported that the incidence of hepatocellular carcinoma (HCC) with non-viral etiologies increased rapidly between 1991 and 2010 in Japan.

Methods

To update this investigation, we enrolled patients who were initially diagnosed as having non-B, non-C HCC at participating hospitals between 2011 and 2015. In addition to the patient characteristics investigated in the previous report, we also investigated the duration of alcohol consumption. The overall survival rate was analyzed using the Kaplan–Meier method, and the hazard function against the body mass index (BMI) was plotted using cubic splines.

Results

A total of 2087 patients were enrolled. The proportion of patients with non-viral etiologies has continued to increase from 10.0% in 1991 to 32.5% in 2015. Patients were also older (median ages, 70–73 years) and more obese (median BMIs, 23.9–24.2 kg/m2), and the proportions of patients with diabetes mellitus (46.1% to 51.6%), hypertension (42.7% to 58.6%), dyslipidemia (14.6% to 22.9%), and fatty liver (24.0% to 28.8%) had all increased significantly. There was a significant inverse relationship between the duration and the amount of daily alcohol consumption. The improvement in the overall survival was relatively small, with a decreased proportion of patients under surveillance (41.3% to 31.6%). A hazard function plot showed a curve similar to that in our previous report, with a lowest hazard of ~ 26 kg/m2.

Conclusions

The proportion of HCC patients with non-viral etiologies continues to increase in Japan. Lifetime total amount of alcohol consumption may be a risk factor.
Appendix
Available only for authorised users
Literature
1.
go back to reference de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190–200.CrossRefPubMedPubMedCentral de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190–200.CrossRefPubMedPubMedCentral
2.
go back to reference Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–9.CrossRefPubMed Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–9.CrossRefPubMed
3.
go back to reference Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–37.CrossRefPubMedPubMedCentral Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–37.CrossRefPubMedPubMedCentral
4.
go back to reference Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355:779–87.CrossRefPubMed Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355:779–87.CrossRefPubMed
5.
go back to reference Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and, mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–38.CrossRefPubMed Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and, mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–38.CrossRefPubMed
6.
go back to reference Collaboration Emerging Risk Factors. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.CrossRef Collaboration Emerging Risk Factors. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.CrossRef
7.
go back to reference Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65.CrossRefPubMedPubMedCentral Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65.CrossRefPubMedPubMedCentral
8.
go back to reference Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21.CrossRefPubMed Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21.CrossRefPubMed
9.
go back to reference El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369–80.CrossRefPubMed El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369–80.CrossRefPubMed
10.
go back to reference El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRef El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRef
11.
go back to reference Islami F, Miller KD, Siegel RL, et al. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67:273–89.CrossRefPubMed Islami F, Miller KD, Siegel RL, et al. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67:273–89.CrossRefPubMed
12.
go back to reference Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350–60.CrossRefPubMed Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350–60.CrossRefPubMed
13.
go back to reference The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma. Clinical practice guidelines for hepatocellular carcinoma—the Japan society of hepatology 2009 update. Hepatol Res. 2010;40:16–47.CrossRef The committee for revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma. Clinical practice guidelines for hepatocellular carcinoma—the Japan society of hepatology 2009 update. Hepatol Res. 2010;40:16–47.CrossRef
14.
go back to reference Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.CrossRefPubMed Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.CrossRefPubMed
15.
go back to reference Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefPubMed Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.CrossRefPubMed
16.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
18.
go back to reference Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer, second. English ed. Tokyo: Kasahara; 2003. Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer, second. English ed. Tokyo: Kasahara; 2003.
20.
go back to reference Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.CrossRefPubMed
21.
go back to reference Sherif ZA, Saeed A, Ghavimi S, et al. Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations. Dig Dis Sci. 2016;61:1214–25.CrossRefPubMedPubMedCentral Sherif ZA, Saeed A, Ghavimi S, et al. Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations. Dig Dis Sci. 2016;61:1214–25.CrossRefPubMedPubMedCentral
22.
go back to reference Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.CrossRefPubMed Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.CrossRefPubMed
23.
go back to reference Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol. 1995;20:127–30.CrossRefPubMed Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol. 1995;20:127–30.CrossRefPubMed
24.
go back to reference Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7:797–801.CrossRefPubMed Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7:797–801.CrossRefPubMed
25.
go back to reference Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9.CrossRefPubMed Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9.CrossRefPubMed
26.
go back to reference Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRefPubMed Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRefPubMed
27.
go back to reference Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol. 2009;15:2506–11.CrossRefPubMedPubMedCentral Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol. 2009;15:2506–11.CrossRefPubMedPubMedCentral
28.
go back to reference Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009;46:279–84.CrossRefPubMed Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009;46:279–84.CrossRefPubMed
29.
go back to reference Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–61.CrossRef Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–61.CrossRef
30.
go back to reference Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323–32.CrossRefPubMed Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323–32.CrossRefPubMed
31.
go back to reference George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745–59.CrossRefPubMed George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745–59.CrossRefPubMed
32.
go back to reference Ho CM, Lee CH, Lee MC, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer. 2018;18:401.CrossRefPubMedPubMedCentral Ho CM, Lee CH, Lee MC, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer. 2018;18:401.CrossRefPubMedPubMedCentral
33.
go back to reference Oishi M, Yamazaki K, Okuguchi F, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32). J Diabetes Investig. 2014;5:581–7.CrossRefPubMed Oishi M, Yamazaki K, Okuguchi F, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32). J Diabetes Investig. 2014;5:581–7.CrossRefPubMed
35.
go back to reference Kohro T, Yamazaki T, Sato H, et al. The impact of a change in hypertension management guidelines on diuretic use in Japan: trends in antihypertensive drug prescriptions from 2005 to 2011. Hypertens Res. 2013;36:559–63.CrossRefPubMed Kohro T, Yamazaki T, Sato H, et al. The impact of a change in hypertension management guidelines on diuretic use in Japan: trends in antihypertensive drug prescriptions from 2005 to 2011. Hypertens Res. 2013;36:559–63.CrossRefPubMed
36.
go back to reference Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127:S87–96.CrossRefPubMed Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127:S87–96.CrossRefPubMed
37.
go back to reference Corrao G, Arico S, Lepore R, et al. Amount and duration of alcohol intake as risk factors of symptomatic liver cirrhosis: a case-control study. J Clin Epidemiol. 1993;46:601–7.CrossRefPubMed Corrao G, Arico S, Lepore R, et al. Amount and duration of alcohol intake as risk factors of symptomatic liver cirrhosis: a case-control study. J Clin Epidemiol. 1993;46:601–7.CrossRefPubMed
38.
go back to reference Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–31.CrossRefPubMed Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323–31.CrossRefPubMed
39.
go back to reference Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5:938–45.CrossRefPubMed Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5:938–45.CrossRefPubMed
40.
go back to reference Ohki T, Tateishi R, Sato T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459–64.CrossRefPubMed Ohki T, Tateishi R, Sato T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459–64.CrossRefPubMed
41.
go back to reference Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26:5576–82.CrossRefPubMed Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26:5576–82.CrossRefPubMed
42.
go back to reference Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131–40.CrossRefPubMed Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131–40.CrossRefPubMed
Metadata
Title
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
Authors
Ryosuke Tateishi
Koji Uchino
Naoto Fujiwara
Tetsuo Takehara
Takeshi Okanoue
Masataka Seike
Hitoshi Yoshiji
Hiroshi Yatsuhashi
Masahito Shimizu
Takuji Torimura
Mitsuhiko Moriyama
Isao Sakaida
Hiroyuki Okada
Tetsuhiro Chiba
Makoto Chuma
Kazuhiko Nakao
Hajime Isomoto
Yutaka Sasaki
Shuichi Kaneko
Tsutomu Masaki
Kazuaki Chayama
Kazuhiko Koike
Publication date
01-04-2019
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 4/2019
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-018-1532-5

Other articles of this Issue 4/2019

Journal of Gastroenterology 4/2019 Go to the issue